Spero Therapeutics gains rights to novel anti-infectives developed at HZI

6 March 2015

Ascenion, the technology transfer partner of Germany’s Helmholtz Center for Infection Research (HZI), has negotiated a licence agreement providing USA-based biotech company Spero Therapeutics with exclusive rights to develop and commercialize a series of novel anti-infective compounds discovered at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), an HZI branch.

Under the terms of the dealt, the HZI is entitled to milestone and royalty payments in line with project progress. In addition, Ascenion has acquired an equity stake in Spero Therapeutics. Potential returns from the future sale of equity will flow to the LifeScience Foundation for the Promotion of Science and Research and eventually be made available for translational research projects of the originating institution. Spero Therapeutics and HIPS have also agreed to collaborate on the early development of the HIPS compounds.

Mix of equity with milestones and royalties keeps the entry barriers low

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK